. 2021 Jan 7;10(1):e01011-20. doi: 10.1128/MRA.01011-20

TABLE 1.

Molecular characteristics and antimicrobial susceptibility profiles for C. difficile isolates in the AR Isolate Bank^a

Isolate no.	BioSample no.	RT	MLST	Toxin profile	tcdC mutation(s)^b	MIC (μg/ml) for:						Mutation and/or gene(s) identified by ResFinder and ARG-ANNOT^c	No. of reads	Genome size (bp)	No. of contigs	N₅₀ (bp)	GC content (%)
Isolate no.	BioSample no.	RT	MLST	Toxin profile	tcdC mutation(s)^b	CRO	CLI	MEM	MTZ	MXF	VAN		No. of reads	Genome size (bp)	No. of contigs	N₅₀ (bp)	GC content (%)
AR-1067	SAMN13029148	027	ST1	tcdA/B⁺, cdtA/B⁺	18bp, Δ117	64	>16	2	1	>8	2	cfrC, dfrf, ermB, tetM, vanG, vanR, vanS, vanT, vanZ, gyrA (Thr82Ile)	1,232,466	4,243,914	301	24,052	28.7
AR-1068	SAMN13029149	056	ST34	tcdA/B⁺, cdtA/B^–	WT	64	4	1	0.25	1	0.5	vanG, vanR, vanS, vanT, vanZ1	1,520,666	4,140,240	323	27,508	28.4
AR-1069	SAMN13029150	015	ST10	tcdA/B⁺, cdtA/B^–	18bp	32	2	2	0.5	2	0.5	vanG, vanR, vanS, vanT, vanZ1	1,155,646	4,340,988	57	227,612	28.2
AR-1070	SAMN13029151	002	ST8	tcdA/B⁺, cdtA/B^–	WT	32	4	1	0.25	2	0.5	vanG, vanR, vanS, vanT, vanZ1	1,484,766	4,272,556	231	41,015	28.4
AR-1071	SAMN13029152	027	ST1	tcdA/B⁺, cdtA/B⁺	18bp, Δ117	64	8	2	1	8	0.5	vanG, vanR, vanS, vanT, vanZ1, gyrA (Thr82Ile)	1,409,698	4,181,997	267	34,074	28.6
AR-1072	SAMN13029153	027	ST1	tcdA/B⁺, cdtA/B⁺	18bp, Δ117	64	>16	2	1	>8	2	cfrC, ermB, vanG, vanR, vanS, vanT, vanZ1, gyrA (Thr82Ile)	1,826,800	4,172,909	222	38,400	28.6
AR-1073	SAMN13029154	020	ST2	tcdA/B⁺, cdtA/B^–	WT	32	4	2	0.5	2	0.5	vanG, vanR, vanS, vanT, vanZ1	1,579,584	4,177,999	117	103,880	28.6
AR-1074	SAMN13029155	002	ST8	tcdA/B⁺, cdtA/B^–	WT	32	8	2	0.5	8	0.5	vanG, vanR, vanS, vanT, vanZ1, gyrA (Thr82Ile)	1,599,852	4,125,816	269	37,978	28.2
AR-1075	SAMN13029156	019	ST67	tcdA/B⁺, cdtA/B⁺	WT	32	4	2	0.5	1	0.5	vanZ1	1,604,652	4,207,539	53	163,554	28.5
AR-1076	SAMN13029157	027	ST1	tcdA/B⁺, cdtA/B⁺	18bp, Δ117	64	8	4	0.25	>8	2	vanG, vanR, vanS, vanT, vanZ1, gyrA (Thr82Ile)	1,871,410	4,107,095	47	174,380	28.5
AR-1077	SAMN13029158	078	ST11	tcdA/B⁺, cdtA/B⁺	39bp, C184T	32	4	1	0.25	1	0.5	ant(6)-ia, spw, tetM	1,451,232	3,918,602	121	64,610	28.5
AR-1078	SAMN13029159	106	ST42	tcdA/B⁺, cdtA/B^–	WT	32	8	2	0.5	2	1	vanG, vanR, vanS, vanT, vanZ1	1,432,018	4,046,102	97	78,397	28.5
AR-1079	SAMN13029160	056	ST34	tcdA/B⁺, cdtA/B^–	WT	32	2	2	0.25	2	0.5	vanG, vanR, vanS, vanT, vanZ1	1,540,522	4,177,894	144	70,736	28.5
AR-1080	SAMN13029161	020	ST2	tcdA/B⁺, cdtA/B^–	WT	16	8	1	0.25	2	0.5	vanG, vanR, vanS, vanT	1,326,024	4,145,293	256	28,424	28.7
AR-1081	SAMN13029162	014	ST110	tcdA/B⁺, cdtA/B^–	WT	32	2	1	0.25	2	0.5	vanG, vanR, vanS, vanT, vanZ1	1,596,282	4,091,127	79	125,940	28.6
AR-1082	SAMN13029163	054	ST43	tcdA/B⁺, cdtA/B^–	WT	32	1	2	0.5	2	0.5	vanG, vanR, vanS, vanT	1,606,932	4,187,731	92	100,411	28.3
AR-1083	SAMN13029164	078	ST11	tcdA/B⁺, cdtA/B⁺	39bp, C184T	32	4	1	0.25	1	0.5	ant(6)-ia, ant(6)-ib, spw, tetM, tet44	1,076,082	3,964,561	153	56,789	28.5
AR-1084	SAMN13029165	002	ST8	tcdA/B⁺, cdtA/B^–	WT	32	2	1	0.25	2	0.5	vanG, vanR, vanS, vanT, vanZ1	1,887,930	4,039,601	47	171,828	28.2
AR-1085	SAMN13029166	106	ST42	tcdA/B⁺, cdtA/B^–	WT	64	8	2	0.25	2	0.5	vanG, vanR, vanS, vanT, vanZ1	1,514,658	4,119,511	223	42,869	28.5
AR-1086	SAMN13029167	015	ST10	tcdA/B⁺, cdtA/B^–	18bp	32	4	1	0.25	1	0.5	vanG, vanR, vanS, vanT, vanZ1	1,520,910	4,319,533	122	73,649	28.3
AR-1087	SAMN13029168	106	ST42	tcdA/B⁺, cdtA/B^–	WT	32	2	1	0.5	2	0.5	vanG, vanR, vanS, vanT, vanZ1	1,670,654	4,022,519	63	151,217	28.4
AR-1088	SAMN13029169	054	ST43	tcdA/B⁺, cdtA/B^–	WT	32	8	2	0.25	1	0.5	vanG, vanR, vanS, vanT	1,178,682	4,094,056	100	78,787	28.3
AR-1089	SAMN13029170	106	ST42	tcdA/B⁺, cdtA/B^–	WT	64	>16	2	0.5	2	0.5	ermB, vanG, vanR, vanS, vanT, vanZ1	2,200,272	4,081,462	51	154,757	28.5
AR-1090	SAMN13029171	014	ST14	tcdA/B⁺, cdtA/B^–	WT	32	>16	2	0.5	2	0.5	ermB, vanG, vanR, vanS, vanT, vanZ1	2,200,528	4,155,416	68	119,271	28.6
AR-1091	SAMN13029172	014	ST2	tcdA/B⁺, cdtA/B^–	WT	64	4	2	0.5	2	0.5	vanG, vanR, vanS, vanT	2,044,134	4,141,305	59	150,646	28.6
AR-1092	SAMN13029173	027	ST1	tcdA/B⁺, cdtA/B⁺	18bp, Δ117	64	>16	4	1	>8	1	ermB, vanG, vanR, vanS, vanT, vanZ1, gyrA (Thr82Ile)	1,720,350	4,134,672	64	122,158	28.6
AR-1093	SAMN13029174	106	ST42	tcdA/B⁺, cdtA/B^–	WT	64	4	2	0.5	2	0.5	vanG, vanR, vanS, vanT, vanZ1	1,201,366	4,071,812	146	62,561	28.5
AR-1094	SAMN13029175	019	ST67	tcdA/B⁺, cdtA/B⁺	WT	32	4	1	0.25	1	0.5	vanZ1	1,935,084	4,139,106	123	74,476	28.4
AR-1095	SAMN13029176	027	ST1	tcdA/B⁺, cdtA/B⁺	18bp, Δ117	128	4	2	0.5	>8	2	vanG, vanR, vanS, vanT, vanZ1, gyrA (Thr82Ile)	925,204	4,103,471	109	91,825	28.5
AR-1096	SAMN13029177	020	ST2	tcdA/B⁺, cdtA/B^–	WT	64	8	2	0.5	2	0.5	vanG, vanR, vanS, vanT	1,946,384	4,095,571	38	204,538	28.6

Abbreviations: CRO, ceftriaxone; CLI, clindamycin; MEM, meropenem; MTZ, metronidazole; MXF, moxifloxacin; VAN, vancomycin; MLST, multilocus sequence type; RT, ribotype; WT, wild type.

tcdC mutations analyzed were Δ117, 18-bp and 39-bp deletions, and the C184T nucleotide point mutation.

The mutations and genes described are for characterization purposes only, and their presence may not predict antimicrobial resistance in C. difficile.